Sabitlenmiş Tweet
Shahad Al Chalaby
114 posts
Shahad Al Chalaby
@shahad_Chalaby
Cardiology Fellow @UCDAVIS 2022- I Chief Resident @AHS-Highland Hospital ‘21 I Mesopotamian 🌍
California, USA Katılım Şubat 2018
229 Takip Edilen136 Takipçiler
Shahad Al Chalaby retweetledi
#TCT2024: #TTVR was approved by @US_FDA for #TricuspidRegurgitation in 2024. Check out the health status analysis of the #TRISCENDII trial led by Drs. @arnoldgehrke, @hahn_rt, @SusheelKodaliMD, @djc795, and team now available in #JACC bit.ly/3Ukv6En #vhdTR
English
Shahad Al Chalaby retweetledi
FAVOR III Europe trial results are in! 🌍 QFR-based strategy in coronary physiology doesn’t match FFR for clinical outcomes at one year. Findings announced at #TCT2024 and published in @TheLancet.
thelancet.com/journals/lance…
#CardioX #CardioTwitter #CardioEd #CardioResearch @BurkhoffMd @djc795 @georgedangas @jgranadacrf @MartyBLeon @MaeharaAkiko @Drroxmehran @sahilparikhmd @triciarawh @TCTConference @jedicath @Dr_ibrahimHarbi @Almanfi_Cardio @BakhshiHooman @ABeneduceMD @nyalborgesmd @aayshacader @BCase07 @NishithChandra @baileyannRN @fischman_david @hect2701 @JGrapsa @HamidNadira @stefan_harb @AmandaLimaMD @evandrofilhobr @GiorgioMedranda @mornei2011 @SrihariNaiduMD @sumonroy_md @DocSavageTJU @Shoaib9702 @poojaotherwise @iamritu @atunuguntla1 @Pooh_Velagapudi @EZancanaroMD @AdrianaCMares @NielsRHolm @IAmDoctorAbhi @KrutarthKPandya @IndahSP_MD @ShariqShamimMD @mirvatalasnag
English
Shahad Al Chalaby retweetledi
Presented at #TCT2024:
In the TRISCEND II randomized trial involving patients with severe tricuspid regurgitation, transcatheter tricuspid-valve replacement was superior to medical therapy at 1 year. Full trial results: nej.md/4dTODm5
English
Shahad Al Chalaby retweetledi
Today’s #TCT2024 late-breaking science session w/ @JACCJournals is your chance to explore research that could reshape ❤️ care!
♦️ Co-STAR
♦️ ACCESS TAVI
♦️ PROTECTED TAVR: US Subgroup
♦️ RHEIA/PARTNER Pooled Analysis in Women
♦️ ALIGN-AR 2 Year
@ThomPilgrim @didier_tchetche
English
Shahad Al Chalaby retweetledi
#SimPub #CircTCT24 PEERLESS Randomized Control Trial: in patients with acute intermediate-risk pulmonary embolism (PE), large-bore mechanical thrombectomy (LBMT) significantly reduced adverse outcomes, comparted with catheter-directed thrombolysis (CDT)
ahajrnls.org/3UuyGvP
English
Wonderful, inspirational & enlightening @crfheart @TCTConference
Cardiovascular Research Foundation@crfheart
✨ Don’t miss #TCT2024 Keynote Speaker @arthurbrooks in the Main Arena! ✨ Learn practical strategies for happiness, purpose, and success as you age. 🌟💪 @drroxmehran @tavrkapadia @DrBillLombardi @KVM83 @ShelleyWood2 @djc795 @jgranadacrf @Drroxmehran @triciarawh @TCTConference
English
Shahad Al Chalaby retweetledi
Listening to @arthurbrooks discuss Strength to Strength at #TCT2024 – powerful insights on achieving lasting success and fulfillment as we transition through life’s stages. Inspiring perspective on finding purpose beyond achievements!"
Dr Roxana Mehran@Drroxmehran
today is our key note speaker Day!!! Arthur Brooks in the Main Arena 9:30 AM. He is brilliant with a lot of good advice for us strivers based on research and data.Enjoy this hour off and focus on your wellbeing. He may even sign your book!! #TCT2024 @crfheart #selfcare
English
Shahad Al Chalaby retweetledi
#TCT2024: In the #DCBBIF trial, Dr. @shaoliang_chen, & colleagues demonstrate that the use of drug-coated balloons for coronary bifurcations with pinched side branches was associated with reduced #MACE at 1 year bit.ly/3Uqy0aR
#JACC #ACCIntl #DCB #CardioX
English
Shahad Al Chalaby retweetledi
@drnvanmieghem @MartyBLeon Results from #TAVRUNLOAD in #JACC show improved #QoL after #TAVR in patients w/ #HFrEF & moderate #vhdAS. No effect on clinical endpoints because of rapid progression to severe AS in control arm that also mandated TAVR. bit.ly/4hoW47I #TCT2024
English
Shahad Al Chalaby retweetledi
#TAVR may offer benefits for patients with asymptomatic severe aortic stenosis. 🫀💡 Findings were unveiled today at #TCT2024 and published in @NEJM. nejm.org/doi/full/10.10…
#CardioX #CardioTwitter #CardioEd #CardioResearch @BurkhoffMd @djc795 @georgedangas @jgranadacrf @MartyBLeon @MaeharaAkiko @Drroxmehran @sahilparikhmd @triciarawh @TCTConference @jedicath @Dr_ibrahimHarbi @Almanfi_Cardio @BakhshiHooman @ABeneduceMD @nyalborgesmd @aayshacader @BCase07 @NishithChandra @baileyannRN @fischman_david @hect2701 @JGrapsa @HamidNadira @stefan_harb @AmandaLimaMD @evandrofilhobr @GiorgioMedranda @mornei2011 @SrihariNaiduMD @sumonroy_md @DocSavageTJU @Shoaib9702 @poojaotherwise @iamritu @atunuguntla1 @Pooh_Velagapudi @EZancanaroMD @AdrianaCMares @NielsRHolm @IAmDoctorAbhi @KrutarthKPandya @IndahSP_MD @ShariqShamimMD @mirvatalasnag
English
Transcatheter Aortic-Valve Replacement for Asymptomatic Severe Aortic Stenosis | New England Journal of Medicine nejm.org/doi/full/10.10… #TCT24
English
Shahad Al Chalaby retweetledi
MIЯVΛƬ #IC ༄ ｡°@mirvatalasnag
#TCT2024 #LBCT #EarlyTAVR @PhilGenereuxMD Patients w asymptomatic, severe AS, a strategy of early TAVR compared w clinical surveillance: Resulted in a significant reduction of the PEP: death, stroke, or unplanned CV hospitalization Multiple endpoint variations demonstrated consistent results Not assoc w excess mortality or stroke Prevented a clinically-meaningful decline in quality of life Improved measures of LV and LA function
English
Shahad Al Chalaby retweetledi
Post-TEER hemodynamic mismatch between residual MR & postprocedural LAP was assoc. w/ a poor prognosis. 6 readily accessible perioperative parameters predict the hemodynamic mismatch. bit.ly/3XZoxta
#JACCINT #TEER #vhdMR
English
Shahad Al Chalaby retweetledi
📰 ICYMI: The newest clinical guideline released by ACC and @American_Heart, in collaboration with 7️⃣ other societies, provides updated recommendations for perioperative cardiovascular management of patients undergoing noncardiac surgery.
➡️ Get the details: bit.ly/4dghj8N
#JACC #CardioX @JACCJournals
English
Shahad Al Chalaby retweetledi
Finally, an AI-powered and less user-dependent way of quantifying mitral regurgitation versus PISA. When we worked with Philips on 3D Auto CFQ, we found that the variability of the 3D-based Rvol measurement was far superior to that of 2D PISA (doi.org/10.1016/j.echo…).
English
Shahad Al Chalaby retweetledi
In this technique you take the ECLA 0.9 coronary laser and you inject contrast (50:50 saline:contrast) at a frequency/fluency profile of 70/70. This creates a micro cavitation effect that allows disruption of calcium behind the stent struts allowing for possible expansion #LaserBomb
Sterling Heights, MI 🇺🇸 English
Shahad Al Chalaby retweetledi
Are you still use contrast ON Laser for recurrent ISR or thrombosis due to under expansion?
This is still an area where IVL still struggles (especially with multiple layers present).
Micari et al demonstrate safety and effectiveness of the technique onlinelibrary.wiley.com/doi/10.1002/cc…
@ccijournal @mirvatalasnag @baileyannRN @adityadoc1 @Tesslagra
Sterling Heights, MI 🇺🇸 English
Shahad Al Chalaby retweetledi
First-in-human experience with EasyCross: a novel #catheter for a safe and correct #aortic valve crossing.
This image, selected by @EuroInterventio , highlights a new device designed to enhance the safety and efficiency of ViV #TAVI procedures, particularly TAV-in-TAV, by reducing attempts to cross the valve and preventing #guidewire misnavigation, thereby minimizing complications and procedure time.
Find out more here ⤵️⤵️
pcronline.com/Cases-resource…
#TAVR #aorticstenosis #innovation #cardioed
English
English
Thrilled to join @PennRadiology next year! Thanks to all my mentors at @MCMC_RadRes! One more year in Philly! 😁
MCMC Diagnostic Radiology Residency Program@MCMC_RadRes
Big congrats to our amazing R3 residents on successful fellowship match! Thrilled you'll all be staying in Philly and joining the University of Pennsylvania @PennRadiology for your fellowships. We are so proud of you all! #MedTwitter #PhillyDocs #fellowmatch #radres #nrmp
English
@NealDixit @MKIttlesonMD @JavedButler1 @BiykemB @kardiologykazi @SJGreene_md @JJheart_doc @ATSandhu @MunirJanmohamed @djc795 @vbluml Great work 👏🏻 congratulations!
English
What is a cost-effective GDMT strategy for HFmrEF/HFpEF?
We built a model w/ clinical trial data (TOPCAT, PARAGON-HF, EMPEROR/DELIVER) and simulated outcomes w/ regimens of MRA/SGLT2i/ARNi.
Best 💊 combo?
MRA + SGLT2i
ARNi ⬇️ value at current 💵
Treat HF with urgency!
English